Effectiveness of levocanidine in combination with metoprolol in the treatment of dilated cardiomyopathy in children and the effect on serum s ST2, TGF-β and cardiac function
QIN Yi1, PENG Jie2, WANG Tao3
1. Department of Pediatrics, Red Cross Hospital of Yulin City, Yulin 537000, China; 2. Ultrasound Department, Affiliated Hospital of Yulin Health School, Yulin 537000, China; 3. Department of Pediatrics, West China Second Hospital, Sichuan University, Chengdu 610000, China
Abstract:Objective:To analyze the effect of levocarnitine combined with metoprolol in the treatment of children with dilated cardiomyopathy, as well as the influence on serum soluble ST2 protein (s ST2), transforming growth factor (TGF) and cardiac function-related indicators.MethodsFrom January 2019 to November 2022, 22 children with Dilated cardiomyopathy admitted to Yulin Red Cross Society Hospital and 70 children with Dilated cardiomyopathy admitted to West China Second Hospital of Sichuan University were selected as research subjects, and divided into experimental group (n=47) and control group (n=45) by the random number table approach. Metoprolol was administered to the control group, while levocarnitine and metoprolol were administered to the experimental group. The clinical efficacy, vital signs, serum s ST2, TGF-β, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), adverse reactions were compared between the two groups.ResultsAfter 4 weeks of treatment, the total effective rate of treatment in experimental group was higher than that in control group (89.36% vs 71.11%). After treatment, the systolic blood pressure and diastolic blood pressure with (114.87±7.16) mmHg and (86.12±5.02) mmHg in experimental group were higher than (110.72±8.04) mmHg and (83.46±5.35) mmHg in control group while the heart rate with (100.34±9.24) beats/min was lower than (105.59±10.63) beats/min in control group. The levels of serum s ST2 and TGF-β in experimental group after treatment were (0.07±0.01) ng/mL and (131.12±10.07) ng/L, which were lower than (0.16±0.04) ng/mL and (185.46±7.41) ng/L in control group. After treatment, the LVESD and LVEDD with (30.71±7.12) mm and (63.28±9.18) mm in experimental group were lower than (36.89±6.56) mm and (70.79±10.56) mm in control group while the LVEF with (49.63±3.35) % was higher compared with (43.29±2.51) % in control group. After treatment, the 6 minutes walking distance with (399.64±59.97) m in experimental group was longer than (309.64±48.79) m in control group, and NT-proBNP with (2411.08±1108.15) ng/L was lower than (3451.14±1567.59) ng/L in control group. There was no significant difference in the incidence of adverse drug reactions.ConclusionLevocarnitine combined with metoprolol has a significant effect on children with dilated cardiomyopathy, and it can effectively improve the vital signs, serum s ST2, TGF-β and cardiac function, without increasing adverse reactions.
覃艺, 彭洁, 王涛. 左卡尼汀联合美托洛尔治疗儿童扩张型心肌病的效果及对血清s ST2、TGF-β及心功能的影响[J]. 金宝搏官方188学报(医学版), 2023, 20(3): 88-91. QIN Yi, PENG Jie, WANG Tao. Effectiveness of levocanidine in combination with metoprolol in the treatment of dilated cardiomyopathy in children and the effect on serum s ST2, TGF-β and cardiac function. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(3): 88-91.